Drug Profile
Research programme: leishmaniasis vaccine - McGill University/Nagasaki University/Ohio State University
Latest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator McGill University; Nagasaki University School of Medicine; Ohio State University
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Leishmaniasis
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for research development in Leishmaniasis(Prevention) in Japan (Parenteral)
- 10 Nov 2015 Early research in Leishmaniasis (Prevention) in Japan (Parenteral)
- 04 Nov 2015 McGill University, Nagasaki University and Ohio State University receives grant from the global Health Innovative Technology Fund for anti-leishmaniasis drug development